Glucose

The exact 10% human infusion has a sourced current Georgian registration with identifiable manufacturer, strength and IV route, while exhaustive current checks record it as not registered in EU/EEA, GB or US. Veterinary administration is off-label; current foreign class labels and veterinary guidance support dextrose rather than any one of these exact products.

IV dextrose is an established, rapidly effective intervention for clinically important hypoglycaemia in dogs and cats and is listed as an essential veterinary medicine. The exact 10% bag can supply a controlled infusion, but routine dog/cat guidance usually targets 1.25–5% after an initial bolus; benefit depends on diagnosing and treating the cause, and comparative exact-product outcome evidence is absent.

At 100 mg/ml and about 505 mOsm/L, this is a hypertonic glucose solution. Excess dose or rate can cause hyperglycaemia, hyperosmolality, osmotic diuresis, dehydration, electrolyte shifts and fluid overload; peripheral infusion risks phlebitis and extravasation injury. Rapid glucose-driven insulin release can worsen hypokalaemia or hypophosphataemia and can produce rebound hypoglycaemia in hyperinsulinaemic disease.

The ready sterile bag permits a controlled central infusion and exact calculation at 0.1 g/ml, but concentrations above 5% are preferably central-line solutions in dogs and cats. Peripheral use generally requires aseptic dilution, compatibility and final-osmolality checks, an infusion pump, frequent bedside glucose measurement and a plan to taper or stop once oral/enteral control or normoglycaemia is sustained.

The exact 10% human infusion has a sourced current Georgian registration with identifiable manufacturer, strength and IV route, while exhaustive current checks record it as not registered in EU/EEA, GB or US. Veterinary administration is off-label; current foreign class labels and veterinary guidance support dextrose rather than any one of these exact products.

IV dextrose is an established, rapidly effective intervention for clinically important hypoglycaemia in dogs and cats and is listed as an essential veterinary medicine. The exact 10% bag can supply a controlled infusion, but routine dog/cat guidance usually targets 1.25–5% after an initial bolus; benefit depends on diagnosing and treating the cause, and comparative exact-product outcome evidence is absent.

At 100 mg/ml and about 505 mOsm/L, this is a hypertonic glucose solution. Excess dose or rate can cause hyperglycaemia, hyperosmolality, osmotic diuresis, dehydration, electrolyte shifts and fluid overload; peripheral infusion risks phlebitis and extravasation injury. Rapid glucose-driven insulin release can worsen hypokalaemia or hypophosphataemia and can produce rebound hypoglycaemia in hyperinsulinaemic disease.

The ready sterile bag permits a controlled central infusion and exact calculation at 0.1 g/ml, but concentrations above 5% are preferably central-line solutions in dogs and cats. Peripheral use generally requires aseptic dilution, compatibility and final-osmolality checks, an infusion pump, frequent bedside glucose measurement and a plan to taper or stop once oral/enteral control or normoglycaemia is sustained.

The exact 10% human infusion has a sourced current Georgian registration with identifiable manufacturer, strength and IV route, while exhaustive current checks record it as not registered in EU/EEA, GB or US. Veterinary administration is off-label; current foreign class labels and veterinary guidance support dextrose rather than any one of these exact products.

IV dextrose is an established, rapidly effective intervention for clinically important hypoglycaemia in dogs and cats and is listed as an essential veterinary medicine. The exact 10% bag can supply a controlled infusion, but routine dog/cat guidance usually targets 1.25–5% after an initial bolus; benefit depends on diagnosing and treating the cause, and comparative exact-product outcome evidence is absent.

At 100 mg/ml and about 505 mOsm/L, this is a hypertonic glucose solution. Excess dose or rate can cause hyperglycaemia, hyperosmolality, osmotic diuresis, dehydration, electrolyte shifts and fluid overload; peripheral infusion risks phlebitis and extravasation injury. Rapid glucose-driven insulin release can worsen hypokalaemia or hypophosphataemia and can produce rebound hypoglycaemia in hyperinsulinaemic disease.

The ready sterile bag permits a controlled central infusion and exact calculation at 0.1 g/ml, but concentrations above 5% are preferably central-line solutions in dogs and cats. Peripheral use generally requires aseptic dilution, compatibility and final-osmolality checks, an infusion pump, frequent bedside glucose measurement and a plan to taper or stop once oral/enteral control or normoglycaemia is sustained.

The exact 10% human infusion has a sourced current Georgian registration with identifiable manufacturer, strength and IV route, while exhaustive current checks record it as not registered in EU/EEA, GB or US. Veterinary administration is off-label; current foreign class labels and veterinary guidance support dextrose rather than any one of these exact products.

IV dextrose is an established, rapidly effective intervention for clinically important hypoglycaemia in dogs and cats and is listed as an essential veterinary medicine. The exact 10% bag can supply a controlled infusion, but routine dog/cat guidance usually targets 1.25–5% after an initial bolus; benefit depends on diagnosing and treating the cause, and comparative exact-product outcome evidence is absent.

At 100 mg/ml and about 505 mOsm/L, this is a hypertonic glucose solution. Excess dose or rate can cause hyperglycaemia, hyperosmolality, osmotic diuresis, dehydration, electrolyte shifts and fluid overload; peripheral infusion risks phlebitis and extravasation injury. Rapid glucose-driven insulin release can worsen hypokalaemia or hypophosphataemia and can produce rebound hypoglycaemia in hyperinsulinaemic disease.

The ready sterile bag permits a controlled central infusion and exact calculation at 0.1 g/ml, but concentrations above 5% are preferably central-line solutions in dogs and cats. Peripheral use generally requires aseptic dilution, compatibility and final-osmolality checks, an infusion pump, frequent bedside glucose measurement and a plan to taper or stop once oral/enteral control or normoglycaemia is sustained.

The exact 10% human infusion has a sourced current Georgian registration with identifiable manufacturer, strength and IV route, while exhaustive current checks record it as not registered in EU/EEA, GB or US. Veterinary administration is off-label; current foreign class labels and veterinary guidance support dextrose rather than any one of these exact products.

IV dextrose is an established, rapidly effective intervention for clinically important hypoglycaemia in dogs and cats and is listed as an essential veterinary medicine. The exact 10% bag can supply a controlled infusion, but routine dog/cat guidance usually targets 1.25–5% after an initial bolus; benefit depends on diagnosing and treating the cause, and comparative exact-product outcome evidence is absent.

At 100 mg/ml and about 505 mOsm/L, this is a hypertonic glucose solution. Excess dose or rate can cause hyperglycaemia, hyperosmolality, osmotic diuresis, dehydration, electrolyte shifts and fluid overload; peripheral infusion risks phlebitis and extravasation injury. Rapid glucose-driven insulin release can worsen hypokalaemia or hypophosphataemia and can produce rebound hypoglycaemia in hyperinsulinaemic disease.

The ready sterile bag permits a controlled central infusion and exact calculation at 0.1 g/ml, but concentrations above 5% are preferably central-line solutions in dogs and cats. Peripheral use generally requires aseptic dilution, compatibility and final-osmolality checks, an infusion pump, frequent bedside glucose measurement and a plan to taper or stop once oral/enteral control or normoglycaemia is sustained.

The exact 10% human infusion has a sourced current Georgian registration with identifiable manufacturer, strength and IV route, while exhaustive current checks record it as not registered in EU/EEA, GB or US. Veterinary administration is off-label; current foreign class labels and veterinary guidance support dextrose rather than any one of these exact products.

IV dextrose is an established, rapidly effective intervention for clinically important hypoglycaemia in dogs and cats and is listed as an essential veterinary medicine. The exact 10% bag can supply a controlled infusion, but routine dog/cat guidance usually targets 1.25–5% after an initial bolus; benefit depends on diagnosing and treating the cause, and comparative exact-product outcome evidence is absent.

At 100 mg/ml and about 505 mOsm/L, this is a hypertonic glucose solution. Excess dose or rate can cause hyperglycaemia, hyperosmolality, osmotic diuresis, dehydration, electrolyte shifts and fluid overload; peripheral infusion risks phlebitis and extravasation injury. Rapid glucose-driven insulin release can worsen hypokalaemia or hypophosphataemia and can produce rebound hypoglycaemia in hyperinsulinaemic disease.

The ready sterile bag permits a controlled central infusion and exact calculation at 0.1 g/ml, but concentrations above 5% are preferably central-line solutions in dogs and cats. Peripheral use generally requires aseptic dilution, compatibility and final-osmolality checks, an infusion pump, frequent bedside glucose measurement and a plan to taper or stop once oral/enteral control or normoglycaemia is sustained.

The exact 10% human infusion has a sourced current Georgian registration with identifiable manufacturer, strength and IV route, while exhaustive current checks record it as not registered in EU/EEA, GB or US. Veterinary administration is off-label; current foreign class labels and veterinary guidance support dextrose rather than any one of these exact products.

IV dextrose is an established, rapidly effective intervention for clinically important hypoglycaemia in dogs and cats and is listed as an essential veterinary medicine. The exact 10% bag can supply a controlled infusion, but routine dog/cat guidance usually targets 1.25–5% after an initial bolus; benefit depends on diagnosing and treating the cause, and comparative exact-product outcome evidence is absent.

At 100 mg/ml and about 505 mOsm/L, this is a hypertonic glucose solution. Excess dose or rate can cause hyperglycaemia, hyperosmolality, osmotic diuresis, dehydration, electrolyte shifts and fluid overload; peripheral infusion risks phlebitis and extravasation injury. Rapid glucose-driven insulin release can worsen hypokalaemia or hypophosphataemia and can produce rebound hypoglycaemia in hyperinsulinaemic disease.

The ready sterile bag permits a controlled central infusion and exact calculation at 0.1 g/ml, but concentrations above 5% are preferably central-line solutions in dogs and cats. Peripheral use generally requires aseptic dilution, compatibility and final-osmolality checks, an infusion pump, frequent bedside glucose measurement and a plan to taper or stop once oral/enteral control or normoglycaemia is sustained.

The exact 10% human infusion has a sourced current Georgian registration with identifiable manufacturer, strength and IV route, while exhaustive current checks record it as not registered in EU/EEA, GB or US. Veterinary administration is off-label; current foreign class labels and veterinary guidance support dextrose rather than any one of these exact products.

IV dextrose is an established, rapidly effective intervention for clinically important hypoglycaemia in dogs and cats and is listed as an essential veterinary medicine. The exact 10% bag can supply a controlled infusion, but routine dog/cat guidance usually targets 1.25–5% after an initial bolus; benefit depends on diagnosing and treating the cause, and comparative exact-product outcome evidence is absent.

At 100 mg/ml and about 505 mOsm/L, this is a hypertonic glucose solution. Excess dose or rate can cause hyperglycaemia, hyperosmolality, osmotic diuresis, dehydration, electrolyte shifts and fluid overload; peripheral infusion risks phlebitis and extravasation injury. Rapid glucose-driven insulin release can worsen hypokalaemia or hypophosphataemia and can produce rebound hypoglycaemia in hyperinsulinaemic disease.

The ready sterile bag permits a controlled central infusion and exact calculation at 0.1 g/ml, but concentrations above 5% are preferably central-line solutions in dogs and cats. Peripheral use generally requires aseptic dilution, compatibility and final-osmolality checks, an infusion pump, frequent bedside glucose measurement and a plan to taper or stop once oral/enteral control or normoglycaemia is sustained.

The exact 10% human infusion has a sourced current Georgian registration with identifiable manufacturer, strength and IV route, while exhaustive current checks record it as not registered in EU/EEA, GB or US. Veterinary administration is off-label; current foreign class labels and veterinary guidance support dextrose rather than any one of these exact products.

IV dextrose is an established, rapidly effective intervention for clinically important hypoglycaemia in dogs and cats and is listed as an essential veterinary medicine. The exact 10% bag can supply a controlled infusion, but routine dog/cat guidance usually targets 1.25–5% after an initial bolus; benefit depends on diagnosing and treating the cause, and comparative exact-product outcome evidence is absent.

At 100 mg/ml and about 505 mOsm/L, this is a hypertonic glucose solution. Excess dose or rate can cause hyperglycaemia, hyperosmolality, osmotic diuresis, dehydration, electrolyte shifts and fluid overload; peripheral infusion risks phlebitis and extravasation injury. Rapid glucose-driven insulin release can worsen hypokalaemia or hypophosphataemia and can produce rebound hypoglycaemia in hyperinsulinaemic disease.

The ready sterile bag permits a controlled central infusion and exact calculation at 0.1 g/ml, but concentrations above 5% are preferably central-line solutions in dogs and cats. Peripheral use generally requires aseptic dilution, compatibility and final-osmolality checks, an infusion pump, frequent bedside glucose measurement and a plan to taper or stop once oral/enteral control or normoglycaemia is sustained.

The exact 10% human infusion has a sourced current Georgian registration with identifiable manufacturer, strength and IV route, while exhaustive current checks record it as not registered in EU/EEA, GB or US. Veterinary administration is off-label; current foreign class labels and veterinary guidance support dextrose rather than any one of these exact products.

IV dextrose is an established, rapidly effective intervention for clinically important hypoglycaemia in dogs and cats and is listed as an essential veterinary medicine. The exact 10% bag can supply a controlled infusion, but routine dog/cat guidance usually targets 1.25–5% after an initial bolus; benefit depends on diagnosing and treating the cause, and comparative exact-product outcome evidence is absent.

At 100 mg/ml and about 505 mOsm/L, this is a hypertonic glucose solution. Excess dose or rate can cause hyperglycaemia, hyperosmolality, osmotic diuresis, dehydration, electrolyte shifts and fluid overload; peripheral infusion risks phlebitis and extravasation injury. Rapid glucose-driven insulin release can worsen hypokalaemia or hypophosphataemia and can produce rebound hypoglycaemia in hyperinsulinaemic disease.

The ready sterile bag permits a controlled central infusion and exact calculation at 0.1 g/ml, but concentrations above 5% are preferably central-line solutions in dogs and cats. Peripheral use generally requires aseptic dilution, compatibility and final-osmolality checks, an infusion pump, frequent bedside glucose measurement and a plan to taper or stop once oral/enteral control or normoglycaemia is sustained.

The exact 10% human infusion has a sourced current Georgian registration with identifiable manufacturer, strength and IV route, while exhaustive current checks record it as not registered in EU/EEA, GB or US. Veterinary administration is off-label; current foreign class labels and veterinary guidance support dextrose rather than any one of these exact products.

IV dextrose is an established, rapidly effective intervention for clinically important hypoglycaemia in dogs and cats and is listed as an essential veterinary medicine. The exact 10% bag can supply a controlled infusion, but routine dog/cat guidance usually targets 1.25–5% after an initial bolus; benefit depends on diagnosing and treating the cause, and comparative exact-product outcome evidence is absent.

At 100 mg/ml and about 505 mOsm/L, this is a hypertonic glucose solution. Excess dose or rate can cause hyperglycaemia, hyperosmolality, osmotic diuresis, dehydration, electrolyte shifts and fluid overload; peripheral infusion risks phlebitis and extravasation injury. Rapid glucose-driven insulin release can worsen hypokalaemia or hypophosphataemia and can produce rebound hypoglycaemia in hyperinsulinaemic disease.

The ready sterile bag permits a controlled central infusion and exact calculation at 0.1 g/ml, but concentrations above 5% are preferably central-line solutions in dogs and cats. Peripheral use generally requires aseptic dilution, compatibility and final-osmolality checks, an infusion pump, frequent bedside glucose measurement and a plan to taper or stop once oral/enteral control or normoglycaemia is sustained.

The exact 10% human infusion has a sourced current Georgian registration with identifiable manufacturer, strength and IV route, while exhaustive current checks record it as not registered in EU/EEA, GB or US. Veterinary administration is off-label; current foreign class labels and veterinary guidance support dextrose rather than any one of these exact products.

IV dextrose is an established, rapidly effective intervention for clinically important hypoglycaemia in dogs and cats and is listed as an essential veterinary medicine. The exact 10% bag can supply a controlled infusion, but routine dog/cat guidance usually targets 1.25–5% after an initial bolus; benefit depends on diagnosing and treating the cause, and comparative exact-product outcome evidence is absent.

At 100 mg/ml and about 505 mOsm/L, this is a hypertonic glucose solution. Excess dose or rate can cause hyperglycaemia, hyperosmolality, osmotic diuresis, dehydration, electrolyte shifts and fluid overload; peripheral infusion risks phlebitis and extravasation injury. Rapid glucose-driven insulin release can worsen hypokalaemia or hypophosphataemia and can produce rebound hypoglycaemia in hyperinsulinaemic disease.

The ready sterile bag permits a controlled central infusion and exact calculation at 0.1 g/ml, but concentrations above 5% are preferably central-line solutions in dogs and cats. Peripheral use generally requires aseptic dilution, compatibility and final-osmolality checks, an infusion pump, frequent bedside glucose measurement and a plan to taper or stop once oral/enteral control or normoglycaemia is sustained.

The dog and cat product holds an Italian national authorisation listed in the EU database (UPD 600000097476), a real regulator record, but it is an older authorisation with no published efficacy data; Georgia lists it as 61-11 with no validity date.

Glucose gives short-lived energy and vitamins help only a true deficiency; no controlled study shows clinical benefit for the labelled supportive uses, and current fluid guidelines use measured fluids and dextrose instead.

The dose is fixed at 10-15 ml regardless of size, giving 20,000-30,000 IU of vitamin D3 and 500-750 mg of glucose per dose; the label excludes hyperglycaemia and the first third of pregnancy and warns of vitamin excess.

Slow IV injection in clinic is straightforward, but the emulsion must not be mixed with other drugs and an opened vial lasts 28 days.

The dog and cat product holds an Italian national authorisation listed in the EU database (UPD 600000097476), a real regulator record, but it is an older authorisation with no published efficacy data; Georgia lists it as 61-11 with no validity date.

Glucose gives short-lived energy and vitamins help only a true deficiency; no controlled study shows clinical benefit for the labelled supportive uses, and current fluid guidelines use measured fluids and dextrose instead.

The same fixed 10-15 ml dose as for dogs gives a 3-4 kg cat roughly 5,000-10,000 IU/kg of vitamin D3 and a large glucose load in one injection; the label excludes hyperglycaemia and the first third of pregnancy and warns of vitamin excess.

10-15 ml is a large single volume for a cat by any route, the IV injection must be slow, and the emulsion must not be mixed with other drugs.